
zzso (also known as zzso is a zzso preparation of the zzso I zzso zzso which has shown zzso activity in phase I and II clinical zzso zzso is a widely used zzso agent with activity in a broad range of tumor zzso This phase I trial was conducted to determine the recommended doses of these agents, and their zzso properties and zzso in patients with advanced solid zzso 

Fourteen patients with advanced and/or zzso solid zzso were enrolled in this zzso The first planned dose level was zzso zzso zzso with zzso 25 zzso administered zzso daily for the first three consecutive days of a zzso zzso Patients were evaluated for zzso and zzso zzso and zzso studies were performed on both zzso 

The recommended phase II dose was determined to be zzso zzso zzso given with 25 zzso zzso zzso zzso was seen in two of three patients at the starting dose zzso Three of 11 patients at the second zzso dose level experienced zzso zzso zzso zzso was also seen in one zzso zzso zzso were generally manageable and included fatigue, zzso and zzso zzso zzso was seen in both zzso zzso and zzso One complete response and three partial responses were zzso 

The recommended phase II dose for this combination is zzso zzso zzso with 25 zzso zzso given as an intravenous infusion on days 1, 2 and 3 of a zzso zzso The main toxicity was zzso zzso evidence of zzso activity was zzso 

